senior management

Califf re-joining FDA would be positive for industry; analyst

With rumours growing that that ex-FDA head Robert Califf looks set to receive President Joe Biden’s nomination to be the next FDA commissioner, at least one analyst thinks the appointment would be a positive for the biopharma industry. Califf was appointed to the helm of the FDA under the Obama administration in 2016, and picked …

Califf re-joining FDA would be positive for industry; analyst Read More »

J&J’s long-serving R&D chief Paul Stoffels announces retirement

Paul Stoffels is bringing a nine-year tenure as head of R&D at Johnson & Johnson to a close, announcing plans to retire at the end of the year. Belgium-born Stoffels has been CSO at J&J since 2012, and was global head of pharma R&D for three years before that whilst also serving as chairman of …

J&J’s long-serving R&D chief Paul Stoffels announces retirement Read More »

Second hedge fund applies pressure on GSK after taking stake

Activist hedge fund Bluebell Capital Partners has joined Elliott Investment in taking a stake in GlaxoSmithKline and pushing for change at the drugmaker. In a letter to GSK chair Sir Jonathan Symonds, Bluebell has called on GSK to ask its chief executive Emma Walmsley to reapply for her job, and carry out a “thorough and …

Second hedge fund applies pressure on GSK after taking stake Read More »

Galapagos’ long-serving CEO Onno van de Stolpe to retire

After 22 years at the helm of Belgian biotech Galapagos, chief executive Onno van de Stolpe has decided it is time to retire and hand the reins to new leadership. He will stay in his role until a successor is found, according to the company, which has kicked off a search for a new CEO. …

Galapagos’ long-serving CEO Onno van de Stolpe to retire Read More »

Alex Gorsky will pass leadership of J&J to Joaquin Duato in January

Johnson & Johnson has appointed Joaquin Duato as chief executive officer to replace long-serving Alex Gorsky, who has been CEO since 2012. Joaquin Duato Gorsky will stay on at the company as executive chairman, but Duato – currently vice chairman at J&J’s executive committee – will take the top job at the company on 3 …

Alex Gorsky will pass leadership of J&J to Joaquin Duato in January Read More »

With Alzheimer’s market opening up, Lilly forms neuroscience unit

Eli Lilly is one of the front runners in the bid to follow Biogen and Eisai onto the market with an anti-amyloid drug for Alzheimer’s disease, and its preparing the ground with a restructuring of its business units. As of 5 September, Lilly’s BioMedicines division will be split in two to form Lilly Neuroscience and …

With Alzheimer’s market opening up, Lilly forms neuroscience unit Read More »

GSK names McNamara as CEO of consumer health spinout

GlaxoSmithKline has said that Brian McNamara – currently head of its three-year-old consumer health joint venture with Pfizer – will retain the top job at the business after it is hived off into a separate company next year. The appointment, which had been expected, was confirmed in a statement by GSK’s board today. McNamara has …

GSK names McNamara as CEO of consumer health spinout Read More »

Arcus’ CMO Grossman jumps ship to join Gilead’s cancer push

Gilead Sciences just forged even closer ties with its cancer drug partner Arcus Biosciences, enticing the biotech’s chief medical officer Bill Grossman to a new role as its head of oncology clinical research. The two companies entered into a 10-year alliance last year, with Gilead claiming certain rights to Arcus clinical and preclinical immuno-oncology candidates …

Arcus’ CMO Grossman jumps ship to join Gilead’s cancer push Read More »

GSK cancer head Hoos exits, takes top role at biotech Scorpion

GlaxoSmithKline’s head of oncology Axel Hoos has resigned from the company, and will take up a new role as chief executive of US biotech Scorpion Therapeutics.  Hoos is leaving GSK after nine years, a period that saw a complete revamp of the unit including the wholesale divestment of cancer drugs to Novartis in a $16 …

GSK cancer head Hoos exits, takes top role at biotech Scorpion Read More »

GSK backs CEO Walmsley, rejecting Elliott’s call to change board

GlaxoSmithKline’s board had responded to the broadside attack delivered by activist investor Elliott Management yesterday, saying it stands firmly behind the leadership of chief executive Emma Walmsley. The drugmaker rejected calls by Elliott to change its board and accelerate the complete divestment of its consumer health unit which is due to be split from the …

GSK backs CEO Walmsley, rejecting Elliott’s call to change board Read More »

Elliott fires broadside at GSK in wake of investor update

GlaxoSmithKline chief executive Emma Walmsley was no doubt hoping that an upbeat assessment of the firm’s prospects at an investor meeting last week would deflect criticism of her leadership from activist investor Elliott Management – but finds herself in the firing line once again today. The US hedge fund, run by billionaire Paul Singer, has …

Elliott fires broadside at GSK in wake of investor update Read More »

Elliott fires broadside at GSK in wake of investor update

GlaxoSmithKline chief executive Emma Walmsley was no doubt hoping that an upbeat assessment of the firm’s prospects at an investor meeting last week would deflect criticism of her leadership from activist investor Elliott Management – but finds herself in the firing line once again today. The US hedge fund, run by billionaire Paul Singer, has …

Elliott fires broadside at GSK in wake of investor update Read More »

Consumer group seeks resignation of top FDA staffers over Aduhelm okay

With the first patient set to receive Biogen’s new Alzheimer’s drug Aduhelm in Rhode Island today, US consumer advocacy organisation Public Citizen is deeply unhappy about the FDA’s approval of the drug – and it wants the scalps of those responsible. In a letter to Secretary of Health and Human Services Xavier Becerra, the director …

Consumer group seeks resignation of top FDA staffers over Aduhelm okay Read More »

Slaoui exits three more companies amid harassment fallout

Moncef Slaoui has stepped down from positions at three more companies, shortly after being dismissed from a firm owned by GlaxoSmithKline for alleged sexual harassment. In the space of 24 hours, Slaoui (61) exited as chairman of US vaccine developer Vaxcyte at the request of the company, and resigned from his role at chief scientific …

Slaoui exits three more companies amid harassment fallout Read More »

Almirall names Nazzi as new CEO after Guenter leaves for Merck

Spanish drugmaker Almirall has lined up its new CEO following the departure of Peter Guenter, who left to lead Merck KGaA’s healthcare unit earlier this month. Gianfranco Nazzi The new CEO is Gianfranco Nazzi, who will take over at Almirall on 1 May. For the last three years he has served as executive vice president, …

Almirall names Nazzi as new CEO after Guenter leaves for Merck Read More »

Guido Rasi steps down, handing the running of EMA to Emer Cooke

EMA executive director Guido Rasi has ended his second term at the helm of the EU medicines regulator, with Emer Cooke taking the wheel and becoming the first women in the role. Rasi’s second five-year term came to an end on Friday (13 November), with his second stint dominated by the move of the EMA …

Guido Rasi steps down, handing the running of EMA to Emer Cooke Read More »

Lilly’s chief digital officer Aarti Shah announces retirement

Eli Lilly’s chief information and digital officer (CIDO) Aarti Shah is leaving the company next year after 27 years at the company. Shah is retiring from a role that only became part of the drugmaker’s executive committee in 2017, reflecting the relatively late acknowledgement of the strategic value of information technology in the pharma industry. …

Lilly’s chief digital officer Aarti Shah announces retirement Read More »

Roger Perlmutter leaves Merck after 7 years, joins board at Insitro

Roger Perlmutter has brought a seven-year stint as head of R&D at Merck & Co/MSD to a close, jumping ship to take on an advisory role at machine-learning specialist Insitro. The 68-year-old – credited with being a catalyst for Merck’s highly lucrative move into cancer immunotherapy – will officially retire from the big pharma company …

Roger Perlmutter leaves Merck after 7 years, joins board at Insitro Read More »